ArriVent FURVENT Trial Failed Primary Endpoint
The Phase 3 study of firmonertinib for lung cancer did not meet its goal for progression-free survival.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you generally trust that pharmaceutical companies provide transparent results during new drug development trials?
ArriVent BioPharma reported that its Phase 3 FURVENT clinical trial failed to meet its primary endpoint of progression-free survival. The study evaluated firmonertinib in patients with previously untreated EGFR exon 20 insertion mutant non-small cell lung cancer.
Why it matters
The trial failure creates significant uncertainty regarding the clinical utility of firmonertinib in this patient population. ArriVent is now reviewing the complete dataset to decide if further development of the drug is viable.
The study utilized a cohort of 398 patients. Grade 3 or higher treatment-related adverse events occurred in 26% of the 240mg arm and 22% of the 160mg arm, compared to 40% in the control group.
The players
ArriVent BioPharma
This biopharmaceutical company based in Newtown Square, Pennsylvania, focuses on developing and commercializing transformative lung cancer therapies.
The details
The FURVENT trial compared firmonertinib administered daily at two dosage levels against a control arm of platinum-based chemotherapy with pemetrexed. Efficacy was measured via blinded independent central review following RECIST 1.1 criteria.
Timeline
October 6, 2026: ArriVent announced the FURVENT trial results.
The Big Picture
The failure of the FURVENT clinical trial highlights the high risks inherent in targeting specific EGFR mutations for lung cancer treatment. This outcome marks a departure from the anticipated positive survival objectives established for this research program.
Patients currently seeking treatment options for EGFR exon 20 insertion mutant NSCLC will not see firmonertinib enter the standard care pathway at this time. This result may encourage patients and their oncologists to focus on alternative chemotherapy or existing approved protocols.
The takeaway
Clinical trials for targeted lung cancer therapies involve significant unpredictability regarding survival outcomes. Developers must frequently re-evaluate drug viability when primary endpoints are not achieved during large-scale global testing.
Further reading
For broader context on oncology research, visit the Cancer section.
Live Poll
Do you generally trust that pharmaceutical companies provide transparent results during new drug development trials?
